Madison Area Lyme Support Group

Please see the complaint below addressed to the Editor-in-Chief, The Lancet Infectious Diseases…

-Carl Tuttle

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: u.hofer@lancet.com
Cc: marco.deambrogi@lancet.com, saleha.hassan@lancet.com, infectiousdiseases@lancet.com, ombudsperson@lancet.com, weboffice@lancet.com, editorial@lancet.com, cope_assistant@publicationethics.org, raymond_dattwyler@nymc.edu, paul_arnaboldi@nymc.edu
Date: 06/02/2024 12:04 PM EDT
Subject: Challenges to the publishing ethics of the journal—eg, conflicts of interest

The Lancet Infectious Diseases

Vaccination hesistancy in Lyme borreliosis
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00221-4/abstract

Raymond J Dattwyler, Paul M Arnaboldi

Published:May 31, 2024

“Although most patients respond well to appropriate antibiotic treatment, a subpopulation of individuals has ongoing symptoms after treatment. The cause of this post-treatment syndrome remains undefined.”  – Raymond J Dattwyler

June 2, 2024

The Lancet Group
125 London Wall
London, EC2Y 5AS, UK
Attn: Ursula Hofer, Editor-in-Chief, The Lancet Infectious Diseases

Dear Dr. Hofer,

Dr. Raymond Dattwyler owns 24 patents for Lyme disease that include diagnostic testing and vaccines both live bacteria and oral. How is this not a conflict of interest when publishing on the subject of vaccination in Lyme borreliosis?

Please correct the COI statement on Dattwyler’s publication.

As someone who has published on the subject of “Bacterial longevity” and “Outgrowing antibiotic action,” you may want to ask Dr. Dattwyler why he has not responded to my 2023 inquiry below:

Respectfully submitted,
Carl Tuttle
Independent Researcher
Hudson, NH USA

Cc: Iratxe Puebla, Facilitation and Integrity Officer
Committee on Publication Ethics (COPE)

Inquiry to Dr. Raymond Dattwyler:

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: Raymond_Dattwyler@nymc.edu
Cc: npjvaccines@nature.com, abarrett@utmb.edu, R.W.Titball@exeter.ac.uk, mgomesso@uthsc.edu
Date: 01/06/2023 2:46 PM EST
Subject: The year that shaped the outcome of the OspA vaccine for human Lyme disease

npj Vaccines Jan 2022

The year that shaped the outcome of the OspA vaccine for human Lyme disease
https://www.nature.com/articles/s41541-022-00429-5

Raymond J. Dattwyler & Maria Gomes-Solecki

Department of Microbiology and Immunology
New York Medical College
Valhalla, NY
Raymond J. Dattwyler, Corresponding Author

Dear Dr. Dattwyler,

I read your manuscript with great interest as you call attention to a treatment-resistant Lyme arthritis with “no evidence of DNA” found in the joints of patients after antibiotic treatment.

For some strange reason however, I could not find the following 1995 publication within your paper identifying treatment-resistant neuroborreliosis:

European Neurology 1995

Seronegative Chronic Relapsing Neuroborreliosis
https://www.karger.com/Article/Abstract/117104

Lawrence C., Lipton R.B., Lowy F.D., Coyle P.K.d

Abstract

We report an unusual patient with evidence of Borrelia burgdorferi infection who experienced repeated neurologic relapses despite aggressive antibiotic therapy. Each course of therapy was associated with a Jarisch-Herxheimer-like reaction. Although the patient never had detectable free antibodies to B. burgdorferi in serum or spinal fluid, the CSF was positive on multiple occasions for complexed anti-B. burgdorferi antibodies, B. burgdorferi nucleic acids and free antigen.

In fact, Dr. Dattwyler there seems to be a great deal of “treatment-resistant” evidence published in multiple journals over the past three decades:
 
Peer Reviewed Evidence of Persistence of Lyme Disease Spirochete Borrelia burgdorferi and Tick-Borne Diseases (700 References)
https://www.dropbox.com/s/n09sk90eo6xz7ua/700%20articles%20LYME%20EvidenceofPersistence-V2.pdf?dl=0

So that brings me to the reason for this email…

Question:

Does a chronic relapsing seronegative disease fit the vaccine model? If not, would that, in and of itself, be the hidden reason for denying chronic (treatment-resistant) Lyme disease for almost three decades? In other words, patent royalties and pharmaceutical profits over lifesaving care?
 
A response to this inquiry is requested.

Carl Tuttle
Hudson, NH

Cc: Alan D.T. Barrett, PhD Editor-in-Chief

Rick Titball, PhD, DSc, Deputy Editor

Letter to the Editor of the BMJ published June 2020
https://www.bmj.com/content/369/bmj.m1041/rr-1

_______________

For the latest Lyme disease ‘vaccine’ candidates:  https://www.precisionvaccinations.com/vaccines/lyme-disease-vaccines